Search - tctmd.com

Displaying 341 - 356 of 356

Sort: Relevancy | Date

News Industry News

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

July 24, 2015

News Industry News

Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet

July 23, 2015

News Industry News

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

July 21, 2015

News Industry News

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

July 09, 2015

News Daily News

Diabetes Often Goes Unrecognized in Patients Hospitalized With Acute MI

May 07, 2015

News Conference News AHA 2014

FACTOR-64: No Benefit to CTA Screening of Asymptomatic Patients with Diabetes

November 16, 2014

News Daily News

Intermittent Claudication Patients Have Better Quality of Life With Invasive Treatment

August 20, 2014

News Daily News

Cardiac Rehab Reduces Late Lumen Loss, Improves Risk Profile in Patients with Long Lesions

April 14, 2014

News Daily News

Diabetes Drug Aleglitazar Fails to Reduce Ischemic Outcomes in Diabetics with Recent ACS

L.A. McKeown

April 11, 2014

News Daily News

High-Risk Subgroups Derive Kidney Protection from Rosuvastatin

Caitlin E. Cox

October 11, 2013

News Conference News ESC 2013

ASSURE: RVX-208 Fails to Stall or Reverse CAD Progression vs. Placebo

September 02, 2013

News Daily News

Women vs. Men in BARI 2D: Equal Survival but Worse Quality of Life

March 09, 2013

News Daily News

Angiotensin Blocker Preserves Endothelial Function Better Than Calcium Antagonist

Jason Kahn

March 05, 2012

News Daily News

Higher BMI Linked to Lower Mortality, More Metabolic Disorders After PCI

L.A. McKeown

April 12, 2011

News Daily News

Pioglitazone Can Decrease Need for Revascularization in Diabetic Patients After BMS

L.A. McKeown

April 07, 2011

CME

Advertisement

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

Diabetes Often Goes Unrecognized in Patients Hospitalized With Acute MI

FACTOR-64: No Benefit to CTA Screening of Asymptomatic Patients with Diabetes

Intermittent Claudication Patients Have Better Quality of Life With Invasive Treatment

Cardiac Rehab Reduces Late Lumen Loss, Improves Risk Profile in Patients with Long Lesions

Diabetes Drug Aleglitazar Fails to Reduce Ischemic Outcomes in Diabetics with Recent ACS

High-Risk Subgroups Derive Kidney Protection from Rosuvastatin

ASSURE: RVX-208 Fails to Stall or Reverse CAD Progression vs. Placebo

Women vs. Men in BARI 2D: Equal Survival but Worse Quality of Life

Angiotensin Blocker Preserves Endothelial Function Better Than Calcium Antagonist

Higher BMI Linked to Lower Mortality, More Metabolic Disorders After PCI

Pioglitazone Can Decrease Need for Revascularization in Diabetic Patients After BMS

Role of Interventional Cardiologists in Secondary Prevention of Acute Coronary Syndromes: Redefining Clinical Practice

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content